These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27566070)

  • 1. Natural Compounds and Neuroprotection: Mechanisms of Action and Novel Delivery Systems.
    Bagli E; Goussia A; Moschos MM; Agnantis N; Kitsos G
    In Vivo; 2016 09-10; 30(5):535-47. PubMed ID: 27566070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology to improve the Alzheimer's disease therapy with natural compounds.
    Ramalho MJ; Andrade S; Loureiro JA; do Carmo Pereira M
    Drug Deliv Transl Res; 2020 Apr; 10(2):380-402. PubMed ID: 31773421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Product Formulations for the Prevention and Treatment of Alzheimer's disease: A Patent Review.
    Koynova R; Tenchov B
    Recent Pat Drug Deliv Formul; 2018; 12(1):23-39. PubMed ID: 29219064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective Properties of Resveratrol and Its Derivatives-Influence on Potential Mechanisms Leading to the Development of Alzheimer's Disease.
    Wiciński M; Domanowska A; Wódkiewicz E; Malinowski B
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amelioration of Mitochondrial Quality Control and Proteostasis by Natural Compounds in Parkinson's Disease Models.
    Cho B; Kim T; Huh YJ; Lee J; Lee YI
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31640129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pharmacological Appraisal of Neuroprotective and Neurorestorative Flavonoids Against Neurodegenerative Diseases.
    Zhao J; Zhu M; Kumar M; Ngo FY; Li Y; Lao L; Rong J
    CNS Neurol Disord Drug Targets; 2019; 18(2):103-114. PubMed ID: 30394219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial mechanisms of estrogen neuroprotection.
    Simpkins JW; Yi KD; Yang SH; Dykens JA
    Biochim Biophys Acta; 2010 Oct; 1800(10):1113-20. PubMed ID: 19931595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rutin as a Natural Therapy for Alzheimer's Disease: Insights into its Mechanisms of Action.
    Habtemariam S
    Curr Med Chem; 2016; 23(9):860-73. PubMed ID: 26898570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.
    Eckert GP; Renner K; Eckert SH; Eckmann J; Hagl S; Abdel-Kader RM; Kurz C; Leuner K; Muller WE
    Mol Neurobiol; 2012 Aug; 46(1):136-50. PubMed ID: 22552779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondria as a pharmacological target: magnum overview.
    Olszewska A; Szewczyk A
    IUBMB Life; 2013 Mar; 65(3):273-81. PubMed ID: 23441041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection against oxidative injury by a nucleic acid-based health product (Squina DNA) through enhancing mitochondrial antioxidant status and functional capacity.
    Lam PY; Chen N; Chiu PY; Leung HY; Ko KM
    J Med Food; 2012 Jul; 15(7):629-38. PubMed ID: 22612294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural Products from Plants and Algae for Treatment of Alzheimer's Disease: A Review.
    Klose J; Griehl C; Roßner S; Schilling S
    Biomolecules; 2022 May; 12(5):. PubMed ID: 35625622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer's disease.
    Govindarajulu M; Ramesh S; Neel L; Fabbrini M; Buabeid M; Fujihashi A; Dwyer D; Lynd T; Shah K; Mohanakumar KP; Smith F; Moore T; Dhanasekaran M
    Neurochem Int; 2021 Mar; 144():104958. PubMed ID: 33444675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of Naturally Derived Alkaloids as Multi-Targeted Therapeutic Agents for Neurodegenerative Diseases.
    Kong YR; Tay KC; Su YX; Wong CK; Tan WN; Khaw KY
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33573300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cationic albumin-conjugated chelating agent as a novel brain drug delivery system in neurodegeneration.
    Kamalinia G; Khodagholi F; Shaerzadeh F; Tavssolian F; Chaharband F; Atyabi F; Sharifzadeh M; Amini M; Dinarvand R
    Chem Biol Drug Des; 2015 Nov; 86(5):1203-14. PubMed ID: 25976552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation.
    Kanubaddi KR; Yang SH; Wu LW; Lee CH; Weng CF
    Int J Nanomedicine; 2018; 13():8473-8485. PubMed ID: 30587972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assay suitability for natural product screening: searching for leads to fight Alzheimer's disease.
    Vasänge M
    Planta Med; 2014 Sep; 80(14):1200-9. PubMed ID: 25221979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitigating effect of chrysin loaded solid lipid nanoparticles against Amyloid β25-35 induced oxidative stress in rat hippocampal region: An efficient formulation approach for Alzheimer's disease.
    Vedagiri A; Thangarajan S
    Neuropeptides; 2016 Aug; 58():111-25. PubMed ID: 27021394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy.
    Plangár I; Zádori D; Klivényi P; Toldi J; Vécsei L
    J Alzheimers Dis; 2011; 24 Suppl 2():199-209. PubMed ID: 21441658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial mechanisms of estrogen neuroprotection.
    Simpkins JW; Dykens JA
    Brain Res Rev; 2008 Mar; 57(2):421-30. PubMed ID: 17512984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.